Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) have revolutionized the therapeutic landscape of many types of solid tumors with superior efficacy and good safety profile.[4] Whether patients with malignancy-associated MN (M-MN) could benefit from ICIs remains elusive. This evidence concerns the gene CD274 and cancer.